Translational Research on Locally Advanced Pancreatic Adenocarcinoma (TRLAPA)
研究概览
详细说明
The trial is prepared to be registered on the clinicaltrail.gov. Quality assurance plan: Every participant is enrolled or excluded by two practiced investigators. And two investigators participated in all steps of the trail, including the record of the data, and the investigators will compare the data. If the data is consistent,the investigators would record the data; if not, the data would be checked and decided by the two investigators. All the steps and data are site monitored and audited by the workers of research and financial department of National Cancer Center/ Cancer Hospital, Chinese Academy of Medical Sciences.
Data check: The investigators compare data entered into the registry against predefined rules for range or consistency with other data fields in the registry.Source data verification to assess the accuracy, completeness, or representativeness of registry data by comparing the data to external data sources, including medical records and electronic case report forms.
Data dictionary that contains detailed descriptions of each variable used by the registry,including the source of the variable, coding information, and normal ranges if relevant.Standard Operating Procedures to address registry operations and analysis activities,such as participants recruitment, data collection, data management, data analysis,reporting for adverse events, and change management. All registry operations would be done according to specific steps, and by two practiced investigators.
Sample size assessment to specify the number of participants or participant years necessary to demonstrate an effect. According to the formula to differ advantages and disadvantages, the investigators need at least 80 participants to take part in the trail.
The investigators can recruit about 20 participants every year according to previous experiences, so the investigators should recruit at least for two years.
Plan for missing data: the investigators would collect as much data as possible, and the investigators exclude the participants who cannot cooperate on recruitment. And the investigators manage situations according to statistical principles where variables are reported as missing, unavailable, "non-reported," uninterpretable, or considered missing because of data inconsistency or out-of-range results.
Statistical analysis plan: Kaplan-Meier method would be used to analyze the difference of survival time between the two groups, and the local control rate of the two groups would be compared by chi square test. Statistical analyses would be performed by using IBM SPSS Statistics(version 20; IBM, Chicago, USA). The level of significance is defined as P < 0.05.
研究类型
注册 (预期的)
阶段
- 不适用
联系人和位置
学习地点
-
-
Beijing
-
Beijing、Beijing、中国、10021
- 招聘中
- Cancer Institute and Hospital ,China Academy of Medical Sciences
-
接触:
- Xu Che, M.D.
- 电话号码:8610-87787120
- 邮箱:xu.che@hotmail.com
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- have cytologic or pathological proof of pancreatic adenocarcinoma without surgery contraindication score of ECOG is between 0 and 1 evaluation of CT is unresectable
Exclusion Criteria:
- metastatic pancreatc adenocarcinoma malignant tumors history allergic to 5-FU have difficulty in swallowing joined other clinical trails cardiac and renal disease active infection
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:单身的
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:Concurrent chemoradiotherapy(CCRT) Group
Concurrent chemoradiotherapy (Total dose: 30-40 Gy; Single dose: 3-4 Gy; Frequency: 10; S-1 orally (80 mg/m2/d),2 weeks) Followed by chemotherapy: Gemcitabine(GEM), 1000 mg/m2 ,Day 1,8 ); taking S-1 orally (80 mg/m2/d, bid on Day 1-14, Q21d, 3 cycles)
|
the 2 arms have different orders of treatment,participants in arm A accept concurrent chemoradiotherapy at first and then accept evalution for surgery.In arm B,participants accept concurrent chemoradiotherapy at first and then accept evalution for surgery.
|
|
实验性的:Chemotherapy Group
Chemotherapy (Gemcitabine(GEM), 1000 mg/m2 ,Day 1,8 ); taking S-1 orally (80 mg/m2/d, bid on Day 1-14, Q21d, 3 cycles) Followed by Concurrent chemoradiotherapy: (Total dose: 30-40 Gy; Single dose: 3-4 Gy; Frequency: 10; S-1 orally (80 mg/m2/d),2 weeks) |
the 2 arms have different orders of treatment,participants in arm A accept concurrent chemoradiotherapy at first and then accept evalution for surgery.In arm B,participants accept concurrent chemoradiotherapy at first and then accept evalution for surgery.
|
研究衡量的是什么?
主要结果指标
结果测量 |
大体时间 |
|---|---|
|
translational resection rate
大体时间:half a year
|
half a year
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
局部控制率
大体时间:2年
|
液晶电阻率
|
2年
|
|
progression-free survival
大体时间:2 years
|
PFS
|
2 years
|
合作者和调查者
调查人员
- 首席研究员:Chengfeng Wang, B.A.、Investigator CancerIHCAMS
研究记录日期
研究主要日期
学习开始
初级完成 (预期的)
研究完成 (预期的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (估计)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.
order of treatment的临床试验
-
Zealand University HospitalUniversity of Copenhagen; Steno Diabetes Center Copenhagen; Holbaek Sygehus招聘中
-
Institute of Liver and Biliary Sciences, India招聘中
-
University of Stellenbosch完全的
-
Compedica IncProfessional Education and Research Institute完全的
-
Bionano GenomicsColumbia University; University of Iowa; Medical College of Wisconsin; Augusta University; University... 和其他合作者招聘中